The Journal of Biological Chemistry (JBC)has retracted two 2003 studies after concluding that figures in the papers had been duplicated, and portions of some figures in one paper “did not accurately represent the results of the experimental conditions.”
The two newly retracted papers have the same last author — Therese Kinsella, a biochemist at the University College Dublin (UCD), who told us the data have been upheld by subsequent research, but that she supports the retractions, which are now part of a UCD investigation.
Butt, however, is not an author of either of the newly retracted papers. Although Butt’s LinkedIn page still lists her as a postdoctoral researcher at UCD, a spokesperson from the institution told us she is no longer based there.
A former graduate student at the University of Colorado Denver has gained three retractions and two expressions of concern (EOC), following an institutional probe into his work.
Last year, we reported on an investigation by the University of Colorado Denver into the research of Rajendra Kadam, which recommended retracting 10 papers. The report also flagged eight additional papers co-authored by Kadam whose data could not be validated, raising “concerns as to the scientific validity and integrity” of the material. A few months later, we reported on some of the notices — four retractions and an EOC — that had begun to appear for Kadam’s manuscripts.
We’ve since discovered more notices, bringing his total to seven retractions and three EOCs.
Kadam was once a prominent member in the lab of Uday Kompella, and often referred to by colleagues as the “golden boy,” according to the institution’s report. In 2012, he won a graduate student symposium award from the American Association of Pharmaceutical Scientists.
falsified and/or fabricated Western blots in eighteen (18) figures and in six (6) published papers.
In 2012, the ORI finding, which resulted in a three-year funding ban (that is now complete), recommended that Elton retract all six papers, one of which had already been retracted at the time of the report.
Four years later, the last of the six papers flagged by the ORI has finally been retracted by Molecular and Cellular Endocrinology.
Once again, this list focuses on duplications — but unlike other duplications, these authors were not at fault. Rather, these retractions occurred because the publishers mistakenly published the same paper twice — the result of a transfer between publishers, for instance, or accidentally publishing the unedited version of the paper. We’re forced to wonder, as we have before, whether saddling researchers’ CVs with a retraction is really the most fair way to handle these cases.
A biotechnology journal has retracted a 14-year-old review after an investigation concluded that the authors had plagiarized from numerous sources.
The last author of the paper — which has been cited 289 times, according to Thomson Reuters Web of Science — told us the authors took a few lines from other reviews, and unintentionally left off the references.
In June 2011, the same author was denied a prestigious fellowship after an anonymous plagiarism allegation was filed against him.
A biomaterials researcher has lost four more papers for figure-related issues such as duplications, bringing his total to seven retractions.
We previously reported on three retractions — two by the Journal of Controlled Release (JCR) — of papers co-authored by Hossein Hosseinkhani, who is currently based at the National Taiwan University of Science and Technology in Taipei. Now, the JCR is pulling four more studies that list Hosseinkhani as a co-author.
The author of a paper about insulin has retracted it due to “extensive text and data overlap” with another paper.
In November 2015, MedChemComm issued an expression of concern (EOC) for the same paper. According to the EOC, the author of the paper, Yong Yang, flagged the paper to the journal, citing problems with authorship and portions of text overlap, which Yang attributed to an editing company.
The editor-in-chief of the journal told us Yang’s institution — China Medical University — carried out an investigation into the case at the journal’s request.
We’ve also found a 2015 retraction for Yang, after he published a paper without the okay of his previous institution in Texas.
A pair of chemical engineers has retracted a paper after another researcher was unable to replicate their work, in a case that we consider an example of doing the right thing.
Dennis Prieve, at Carnegie Mellon University, was interested in applying the paper — on how systems of molecules known as “reverse micelles” conduct electrical charge — to his own work, but was having trouble repeating the calculations. So Prieve contacted the authors — John Berg and his PhD student Edward Michor, based at the University of Washington — who supplied him with their original data.
It took several weeks of back and forth to figure out the problem, Michor told us, as the paper was published in 2012, so he had to decipher his old notes. When they found that several incorrect values were used in the paper, the authors issued a retraction notice, published in March:
A publisher has retracted a chapter from a book on flow cytometry after determining the authors plagiarized some material — but noted that because the authors cited the article they lifted from, they likely acted “in good faith.”
We were tipped off to this retraction from the authors of the review article the chapter plagiarized from, who told us they were upset by the incident and doubted whether the authors had performed the experiments they described in the chapter.
More broadly, the retraction raises an important question: How can publishers retract one chapter of a book, leaving the rest intact?